Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) – Drugs In Development, 2021

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) – Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 51 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 27 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Infectious Disease, Undisclosed, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Multiple Myeloma (Kahler Disease), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Solid Tumor, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Unspecified, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), CNS Lymphoma, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Diastolic Heart Failure, Dilated Cardiomyopathy, Distal Symmetric Polyneuropathy, Fibrosis, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Idiopathic Pulmonary Fibrosis, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproliferative Disorders, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Tauopathies, Ulcerative Colitis, Unspecified B-Cell Lymphomas and Vulvar Cancer.

The latest report Histone Deacetylase 6 – Drugs In Development, 2021, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

– The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

– The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Annji Pharmaceutical Co Ltd

ATP Biopharm

Augustine Therapeutics

Beijing Konruns Pharmaceutical Co Ltd

Bristol Myers Squibb Co

Chong Kun Dang Pharmaceutical Corp

Convalife

CStone Pharmaceuticals Co Ltd

Curis Inc

Eikonizo Therapeutics Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hillstream BioPharma Inc

Jubilant Therapeutics Inc

Kancera AB

Karus Therapeutics Ltd

KYAN Therapeutics Inc

Medivir AB

Merck & Co Inc

Mycovia Pharmaceuticals Inc

OnKure Inc

Oryzon Genomics SA

Quimatryx SL

Shuttle Pharmaceuticals Inc

SK Biopharmaceuticals Co Ltd

Starwise Therapeutics LLC

Tenaya Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Overview

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Therapeutics Development

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Therapeutics Assessment

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Companies Involved in Therapeutics Development

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Drug Profiles

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Dormant Products

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Annji Pharmaceutical Co Ltd, 2021

Pipeline by ATP Biopharm, 2021

Pipeline by Augustine Therapeutics, 2021

Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2021

Pipeline by Bristol Myers Squibb Co, 2021

Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021

Pipeline by Convalife, 2021

Pipeline by CStone Pharmaceuticals Co Ltd, 2021

Pipeline by Curis Inc, 2021

Pipeline by Eikonizo Therapeutics Inc, 2021

Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2021

Pipeline by Hillstream BioPharma Inc, 2021

Pipeline by Jubilant Therapeutics Inc, 2021

Pipeline by Kancera AB, 2021

Pipeline by Karus Therapeutics Ltd, 2021

Pipeline by KYAN Therapeutics Inc, 2021

Pipeline by Medivir AB, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Mycovia Pharmaceuticals Inc, 2021

Pipeline by OnKure Inc, 2021

Pipeline by Oryzon Genomics SA, 2021

Pipeline by Quimatryx SL, 2021

Pipeline by Shuttle Pharmaceuticals Inc, 2021

Pipeline by SK Biopharmaceuticals Co Ltd, 2021

Pipeline by Starwise Therapeutics LLC, 2021

Pipeline by Tenaya Therapeutics Inc, 2021

Dormant Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports